Biotech companies at World Vaccine Congress 2027
Mar 8–11, 2027 Washington, DC ~3k attendees Website
24 biotech companies are at World Vaccine Congress 2027 — 19 presentations on the program and 7 with a booth in the exhibit hall. Most represented: Akagera Medicines (2 on the program), Anixa Biosciences (2 on the program), GPN Vaccines (2 on the program). 10 of them have their own page in this guide. As of Oct 8, 2026.
Topic
Top represented
Showing 1–19 of 24 organizations
| Organization | World Vaccine Congress 2027 Attendance |
|---|---|
Akagera Medicines Waltham, MA | |
Developer of liposomal antibacterial drugs for drug-resistant tuberculosis and MRSA, with vaccine candidates for tuberculosis, Lassa fever, HIV, RSV and influenza. | Talk Mon Mar 8 10:00 Vaccine Technology Workshop New vaccine technologies, from machine learning that pairs adjuvants with antigens to self-amplifying RNA and a liposome-adjuvanted malaria vaccine. |
Anixa Biosciences San Jose, CA | |
Biotech developing a preventive breast cancer vaccine with Cleveland Clinic and a CAR-T therapy for ovarian cancer. | |
Biotech developing next-generation broad-spectrum vaccines, with candidates in clinical trials. | Talk Mon Mar 8 10:00 AMR Workshop How vaccines, antibodies and phage therapy can be developed, funded and used against drug-resistant bacteria, from infant infections to livestock. |
HDT Bio Seattle, WA | |
Develops RNA vaccines and immunotherapies on a nanoparticle delivery platform for infectious diseases and cancer. | |
ModeX Therapeutics Natick, MA | |
OPKO Health company developing multispecific antibodies and vaccines against infectious diseases and cancer. | Talk Mon Mar 8 10:00 Antibodies for Infectious Diseases Workshop Research on antibody medicines that treat or prevent infectious diseases. Talk Mon Mar 8 10:00 HIV Vaccines Workshop Where the search for an HIV vaccine stands, from laboratory advances and ongoing clinical trials to plans for fair global access. |
Biotech developing bacterial vaccines, including a Klebsiella vaccine. | Talk Mon Mar 8 10:00 AMR Workshop How vaccines, antibodies and phage therapy can be developed, funded and used against drug-resistant bacteria, from infant infections to livestock. Panel Wed Mar 10 09:10 Panel: Pharma Ready: What It Really Takes to Seal the Deal What large drug companies look for before partnering with a young vaccine company, from manufacturing readiness and patents to timing the conversation. |
Vaxcyte San Carlos, CA | |
Develops broad-spectrum conjugate vaccines, led by a 31-valent pneumococcal vaccine candidate. | Panel Wed Mar 10 09:10 Panel: Pharma Ready: What It Really Takes to Seal the Deal What large drug companies look for before partnering with a young vaccine company, from manufacturing readiness and patents to timing the conversation. |
Vaxart South San Francisco, CA | |
Develops oral vaccines in tablet form, with candidates against COVID-19 and norovirus. | Booth Exhibiting (no floor booth listed) |
Arcturus Therapeutics San Diego, CA | |
Develops self-amplifying mRNA vaccines and mRNA medicines, including a self-amplifying COVID-19 vaccine approved in Japan and Europe. | Talk Mon Mar 8 10:00 Vaccine Technology Workshop New vaccine technologies, from machine learning that pairs adjuvants with antigens to self-amplifying RNA and a liposome-adjuvanted malaria vaccine. |
BiomEdit Fishers, IN | |
Animal health company developing microbiome-based products for livestock and pets. | Talk Wed Mar 10 09:10 |
Dalan Animal Health Athens, GA | |
Develops vaccines for insects, starting with the first USDA-licensed honeybee vaccine against American foulbrood. | Talk Wed Mar 10 09:10 |
GigaGen South San Francisco, CA | |
Grifols subsidiary developing recombinant polyclonal antibody therapies from human donor B cells, including against infectious diseases. | Talk Mon Mar 8 10:00 Antibodies for Infectious Diseases Workshop Research on antibody medicines that treat or prevent infectious diseases. |
LimmaTech Biologics Schlieren, Switzerland | |
Swiss biotech developing vaccines against bacterial infections and antimicrobial resistance, including Staphylococcus aureus and Shigella. | Talk Mon Mar 8 10:00 AMR Workshop How vaccines, antibodies and phage therapy can be developed, funded and used against drug-resistant bacteria, from infant infections to livestock. |
Montani Biotechnologies Morgantown, WV | |
Developer of mRNA immunotherapies delivered in lipid nanoparticles, aimed at personalized cancer treatments and disease-modifying therapies. | Talk Mon Mar 8 10:00 Vaccine Technology Workshop New vaccine technologies, from machine learning that pairs adjuvants with antigens to self-amplifying RNA and a liposome-adjuvanted malaria vaccine. |
myNEO Therapeutics Ghent, Belgium | |
Belgian biotech using machine learning on tumour data to find targets for personalized cancer vaccines and immunotherapies. | |
Rumin8 Perth, Australia | |
Develops feed additives and boluses that reduce methane emissions from cattle. | Talk Wed Mar 10 09:10 |
Acuitas Therapeutics Vancouver, Canada | |
Develops lipid nanoparticle (LNP) delivery systems for mRNA vaccines and therapeutics, licensed to partner companies. | Booth Exhibiting (no floor booth listed) |
Spanish vaccine company in the Zendal group developing and manufacturing the MTBVAC tuberculosis vaccine. | |
Vaxine Adelaide, Australia | |
Australian biotech developing vaccines and the Advax adjuvant. |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World Vaccine Congress 2027 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by the World Vaccine Congress or its organizers. Submit a correction